Jazz Pharmaceuticals

News

Jazz Pharmaceuticals has been granted US approval for two combinations of its cancer drug Ziihera HER2+ advanced GEA.

News

Jazz Pharma has dipped its toe into the M&A water again, agreeing to buy rare epilepsy drug developer Actio Bio for $820m upfront.

News

Jazz Pharma has made a big move into T-cell engagers (TCEs) for solid tumours, via an alliance with Canadian biotech AbCellera.

News

Jazz's biliary tract cancer drug Ziihera and Lilly's Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance.

News

Servier has made a takeover offer for Day One and its fast-growing glioma therapy Ojemda, as it pitches to drive sales above €10bn by 2030.

News

Can FDA approval of Jazz Pharma's Zepzelca in a combination regimen for extensive-stage small cell lung cancer return sales of the drug to growth?